Skip to content
type1.science
Phase 2TerminatedNCT06025110

STRIDE siplizumab in adults with new-onset T1D

Terminated randomized phase-2 study of the anti-CD2 antibody siplizumab in adults with new-onset T1D. The sponsor attributed the early stop to business reasons rather than safety, efficacy, or regulatory concerns; no results are posted.

Primary endpoints

  • Change from baseline in beta-cell function versus placebo at week 52

Results so far

No results posted. The trial enrolled nine participants rather than the planned 114 and ended on 24 July 2025. The sponsor says it was terminated for business reasons and that the decision was not related to safety, efficacy, or regulatory concerns. That statement explains this study's stop reason; it is not evidence that siplizumab is safe or effective in T1D.